Estrella Immunopharma Inc. (ESLA : NASDAQ)
Common Stock
Follow ESLA
ESLA
Estrella Immunopharma Inc.
WealthAwesomePerformance
1 Day
+45.40%
1 Week
+78.76%
1 Month
+82.24%
YTD
-26.02%
The Tuesday Stock Pick · free, every tuesday morning. One Canadian stock and the case for it.
Key Statistics
Market Cap
$22.35M
52W High
$2.43
52W Low
$0.24
P/E Ratio
-
50 Day MA
$0.55
200 Day MA
$0.98
Beta
0.89
Dividend Yield
-
Performance history
ESLA returns since 2026
Estrella Immunopharma Inc. has traded since Jun 2026 in our data. Its deepest fall was −69.8% (Jun 2026 to Oct 2026).
1 year / yr
—
3 years / yr
—
5 years / yr
—
10 years / yr
—
Calendar-year returns
- 2026*−26.0%
* Partial year (first year of data, or year to date).
$10,000 invested in ESLA
- 2026 (start of our data)$7,398
- All-time high in our data
- $1 on Jun 30, 2026 · now −28.2%
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Jun 2026 to Nov 2026. Past returns do not predict future ones.
Awesome Portfolio™
Looking past ESLA? Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/10/2026 | $0.53 | $0.77 | $0.53 | $0.75 | $0.75 | 3,753,389 |
| 11/9/2026 | $0.43 | $0.60 | $0.43 | $0.51 | $0.51 | 3,894,646 |
| 11/6/2026 | $0.40 | $0.45 | $0.37 | $0.38 | $0.38 | 140,400 |
| 11/5/2026 | $0.44 | $0.44 | $0.40 | $0.41 | $0.41 | 162,761 |
| 11/4/2026 | $0.44 | $0.48 | $0.40 | $0.44 | $0.44 | 128,700 |
| 11/3/2026 | $0.43 | $0.47 | $0.35 | $0.42 | $0.42 | 526,282 |
| 11/2/2026 | $0.64 | $0.64 | $0.42 | $0.43 | $0.43 | 612,597 |
| 10/30/2026 | $0.72 | $0.79 | $0.62 | $0.64 | $0.64 | 165,700 |
| 10/29/2026 | $0.81 | $0.82 | $0.70 | $0.73 | $0.73 | 270,199 |
| 10/28/2026 | $0.92 | $0.99 | $0.75 | $0.82 | $0.82 | 495,004 |
Analyst Price Targets
Based on analyst covering ESLA · as of Oct 5, 2026
Wall Street analysts forecast ESLA stock price to rise 1506.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
US$12.00
+1506.0% Upside
Current Price
US$0.75
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ESLA's historical volatility
30-Day Vol
313.7%
Annualized
90-Day Vol
191.0%
Annualized
Trend (90d)
-7.1%
Annualized drift
90d Mean
US$0.73
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$0.74 | US$0.25 – US$2.19 |
| 60 trading days | US$0.73 | US$0.16 – US$3.39 |
| 90 trading days | US$0.73 | US$0.11 – US$4.75 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Estrella Immunopharma Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Financials
- Revenue (TTM)
- $0
- EBITDA
- -
- Profit Margin
- 0.00%
- ROE (TTM)
- -268.50%
- EPS (Diluted)
- -0.34
- Book Value
- -0.17
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Free newsletter
The Tuesday Stock Pick
One Canadian stock and the case for it
- The name with the biggest gap to analyst targets
- The chart, insider buying and what is driving it
- A plain-English bottom line, no hype
Explore More
Common Questions About ESLA.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| SMX | SMX (Security Matters) Public Limited Company Class A Ordinary Shares | $19.25 | +105.88% |
| PEPG | PepGen Ltd | $4.61 | +92.89% |
| TTEC | TTEC Holdings Inc | $2.40 | +72.04% |
| NNOX | Nano X Imaging Ltd | $0.37 | +59.80% |
| TANH | Tantech Holdings Ltd | $30.56 | +58.01% |
| AACG | ATA Creativity Global | $0.89 | +52.14% |
| MNDO | MIND CTI Ltd | $1.26 | +44.83% |
| LGVN | Longeveron LLC | $2.84 | +41.29% |